Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

NCT05561387 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

510

Enrollment

NETWORK

Sponsor class

Conditions

Plasma Cell Myeloma

Interventions

DRUG: Bortezomib
DRUG: Daratumumab and Hyaluronidase-fihj
DRUG: Dexamethasone
DRUG: Lenalidomide
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]